How does the anti-RIgG(HL)-C-MMAE ADC induce cell death?

The anti-RIgG(HL)-C-MMAE ADC targets cells with a mechanism that involves binding to rabbit IgG, followed by internalization. The MMAE, a microtubule-inhibiting agent, is then released within the cell, where it disrupts microtubule dynamics, ultimately leading to cell death.

Can the anti-RIgG(HL)-C-MMAE ADC be used in therapeutic applications directly?

The anti-RIgG(HL)-C-MMAE ADC is primarily designed for pre-screening rabbit monoclonal antibodies as ADC candidates and is not intended for direct therapeutic applications. Its primary use is in research and development settings to assess the potential of new ADC therapies.

What makes the anti-RIgG(HL)-C-MMAE ADC an economical choice for pre-screening applications?

The anti-RIgG(HL)-C-MMAE ADC provides a cost-effective alternative for pre-screening due to its efficient targeting and delivery mechanism, which allows researchers to evaluate the effectiveness of potential ADC candidates without the need for extensive initial investment in antibody development.

How does MMAE function as a cytotoxic agent in the anti-RIgG(HL)-C-MMAE ADC?

MMAE functions by binding to tubulins within the cell, disrupting microtubule dynamics which are crucial for cell division and vital cellular functions. This disruption leads to cell cycle arrest and apoptosis, making MMAE an effective cytotoxic agent.

What safety measures should be taken while handling the anti-RIgG(HL)-C-MMAE ADC?

Due to its cytotoxic nature, it is essential to handle the anti-RIgG(HL)-C-MMAE ADC with care. Appropriate safety measures include wearing gloves, protective clothing, and safety glasses, and handling the compound in a well-ventilated area.

Can the anti-RIgG(HL)-C-MMAE ADC be used with all types of rabbit monoclonal antibodies?

The ADC is specifically designed to work with rabbit monoclonal antibodies targeting antigens that can internalize upon antibody binding. It is important to confirm the internalization capability of the primary antibody to ensure the efficacy of the ADC.

Home
Products
Anti-Ab ADCs
IgG (H+L)
anti-RIgG(HL)-C-MMAE ADC

anti-RIgG(HL)-C-MMAE ADC (CAT#: ADC-AA-036)

This ADC product is comprised of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a cleavable linker to MMAE. The antibody portion is a secondary antibody and the drug portion, MMAE, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG(H+L)

Overview
IgG antibody subtype is the most abundant serum immunoglobulins of the immune system, which is a protein complex composed of four peptide chains—two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers. IgG is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses.

Overview
anti-rabbit IgG(H+L) specific polyclonal IgG antibody

Species Reactivity
Rabbit

Name
Cleavable linkers

Description
Cleavable linkers rely on the physiological stimuli, which mainly include chemically cleavable linkers and enzymatically cleavable linkers. Chemically cleavable linkers including acid-labile linkers and disulfide linkers. For acid-labile linkers, intracellular release of payloads relies on the different pH between endosomes/lysosomes and blood. The release of disulﬁde-linked drugs is controlled by the factors in intracellular environment. Enzymatically cleavable linkers, peptide linkers and β-glucuronide linkers, are sensitive to enzymes located in cytoplasm.

Name
MMAE (Monomethyl auristatin E)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-036. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Exceptional Tool for Pre-screening

The anti-RIgG(HL)-C-MMAE ADC from Creative Biolabs excels in interrupting microtubule dynamics, proving vital for our antibody screening.

Excellent

Efficient and Safe

We've used the anti-RIgG(HL)-C-MMAE ADC for cytotoxic studies with no observed toxicity in absence of a primary antibody. Highly effective and reliable.

Excellent

Revolutionary in Antibody Research! This ADC product seamlessly integrates with our protocols for studying IgG interactions and their impact on infections. A must-have for any serious lab.

Excellent

Top-Notch Quality and Efficacy

Using the anti-RIgG(HL)-C-MMAE ADC, we've observed precise cell death induction in targeted experiments. Creative Biolabs delivers both safety and performance

Excellent

A Research Breakthrough

The dual functionality of targeting and cytotoxicity in one ADC product has streamlined our workflows and enhanced our output significantly.

Excellent

Invaluable for Immunological Studies! The specific action of the anti-RIgG(HL)-C-MMAE ADC on tubulins has made it indispensable for our research into antibody mechanisms.

Q: 1: How does the anti-RIgG(HL)-C-MMAE ADC induce cell death?
A: The anti-RIgG(HL)-C-MMAE ADC targets cells with a mechanism that involves binding to rabbit IgG, followed by internalization. The MMAE, a microtubule-inhibiting agent, is then released within the cell, where it disrupts microtubule dynamics, ultimately leading to cell death.
Q: 2: Can the anti-RIgG(HL)-C-MMAE ADC be used in therapeutic applications directly?
A: The anti-RIgG(HL)-C-MMAE ADC is primarily designed for pre-screening rabbit monoclonal antibodies as ADC candidates and is not intended for direct therapeutic applications. Its primary use is in research and development settings to assess the potential of new ADC therapies.
Q: 3: What makes the anti-RIgG(HL)-C-MMAE ADC an economical choice for pre-screening applications?
A: The anti-RIgG(HL)-C-MMAE ADC provides a cost-effective alternative for pre-screening due to its efficient targeting and delivery mechanism, which allows researchers to evaluate the effectiveness of potential ADC candidates without the need for extensive initial investment in antibody development.
Q: 4: How does MMAE function as a cytotoxic agent in the anti-RIgG(HL)-C-MMAE ADC?
A: MMAE functions by binding to tubulins within the cell, disrupting microtubule dynamics which are crucial for cell division and vital cellular functions. This disruption leads to cell cycle arrest and apoptosis, making MMAE an effective cytotoxic agent.
Q: 5: What safety measures should be taken while handling the anti-RIgG(HL)-C-MMAE ADC?
A: Due to its cytotoxic nature, it is essential to handle the anti-RIgG(HL)-C-MMAE ADC with care. Appropriate safety measures include wearing gloves, protective clothing, and safety glasses, and handling the compound in a well-ventilated area.
Q: 6: Can the anti-RIgG(HL)-C-MMAE ADC be used with all types of rabbit monoclonal antibodies?
A: The ADC is specifically designed to work with rabbit monoclonal antibodies targeting antigens that can internalize upon antibody binding. It is important to confirm the internalization capability of the primary antibody to ensure the efficacy of the ADC.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-037	anti-RIgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-066	Anti-Rat IgG(H+L)-C-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)
ADC-AA-035	anti-RIgG(HL)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-047	anti-Rat IgG(HL)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-062	Anti-HIgG(Fc)Fab-C-DX8951 ADC	Cleavable linkers	DX8953
ADC-AA-064	Anti-HIgG(Fab)-C-MMAF ADC	Cleavable linkers	MMAF
ADC-AA-010	anti-HIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
WJY-0423-LS106	Protein A-Calicheamicin ADC	Cleavable linkers	Calicheamicin

CAT#	Product Name	Linker	Payload
ADC-AA-056	Anti-MIgG-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-052	Protein A-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-W-565	Anti-EDNRB-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-011	anti-HIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-W-462	Anti-GPNMB-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.